Molecular epidemiology of newly acquired hepatitis C infections in England 2008-2011: Genotype, phylogeny and mutation analysis

Journal of Clinical Virology

Volumn 64, Issue , 2015, Pages 6-11

  May, Shoshanna ^a   Ngui, Siew Lin ^a   Collins, Sarah ^a   Lattimore, Sam ^a   Ramsay, Mary ^a   Tedder, Richard S ^a,b,c   Ijaz, Samreen ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Genotype; Hepatitis C virus; Molecular epidemiology; Risk behavioural factors

Indexed keywords

AMINO ACID; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DEMOGRAPHY; EPIDEMIC; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR PHYLOGENY; MUTATIONAL ANALYSIS; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; UNITED KINGDOM; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION; ADDICTION; ADOLESCENT; COMPLICATION; EPIDEMIOLOGICAL MONITORING; GENETICS; HEPACIVIRUS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; TIME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENGLAND; EPIDEMIOLOGICAL MONITORING; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; PHYLOGENY; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 84923346747     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.12.014     Document Type: Article

References (36)

1. Targeting Testing in England, (2011).
2. Hepatitis C in the UK, (2014) 29-9.
3. Abdul-Quader A.S., Feelemyer J., Modi S., Stein E.S., Briceno A., Semaan S., Horvath T., Kennedy G.E., Des Jarlais D.C. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013, 17:2878-2892.
4. Akhavan S., Schnuriger A., Lebray P., Benhamou Y., Poynard T., Thibault V. Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV. J. Infect. Dis. 2009, 200:524-527.
5. Bae A., Sun S.C., Qi X., Chen X., Ku K., Worth A., Wong K.A., Harris J., Miller M.D., Mo H. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob. Agents Chemother. 2010, 54:5288-5297.
6. Bartels D.J., Zhou Y., Zhang E.Z., Marcial M., Byrn R.A., Pfeiffer T., Tigges A.M., Adiwijaya B.S., Lin C., Kwong A.D., Kieffer T.L. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 2008, 198:800-807.
7. Bartenschlager R., Penin F., Lohmann V., Andrà P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011, 19:95-103.
8. Bradshaw D., Matthews G., Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM?. Curr. Opin. Infect. Dis. 2013, 26:66-72.
9. Brant L.J., Ramsay M.E., Balogun M.A., Boxall E., Hale A., Hurrelle M., Kaluba L., Klapper P., Lewis D., Patel B.C., Parry J., Irving W.L. Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. J. Viral Hepat. 2008, 15:871-877.
10. Brant L.J., Ramsay M.E., Tweed E., Hale A., Hurrelle M., Klapper P., Ngui S.L. Planning for the healthcare burden of hepatitis C infection: hepatitis C genotypes identified in England, 2002-2007. J. Clin. Virol. 2010, 48:115-119.
11. Chae H.B., Park S.M., Youn S.J. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Sci. World J. 2013, 704912.
12. Colson P., Brouk N., Lembo F., Castellani P., Tamalet C., Gerolami R. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology 2008, 47:766-767.
13. Franco S., Bellido R., Aparicio E., Canete N., Garcia-Retortillo M., Sola R., Tural C., Clotet B., Paredes R., Martinez M.A. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. J. Viral Hepat. 2011, 18:e578-e582.
14. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 2011, 55:192-206.
15. Hall T. Bioedit: a user friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucl. Acids Symp. Ser. 1999, 41:95-98.
16. Harris K.A., Gilham C., Mortimer P.P., Teo C.G. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J. Med. Virol. 1999, 58:127-131.
17. Harris M., Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'. Int. J. Drug Policy 2013, 24:e43-e50.
18. Hosein S.R., Wilson D.P. HIV, HCV and drug use in men who have sex with men. Lancet 2013, 382:1095-1096.
19. Imhof I., Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1-6. J. Virol. 2010, 84:4597-4610.
20. Kirby T., Thornber-Dunwell M. New HIV diagnoses in London's gay men continue to soar. Lancet 2013, 382:295.
21. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., Lee B., Heckerman D., Carlson J., Reyor L.L., Kleyman M., McMahon C.M., Birch C., Schulze Zur W.J., Ledlie T., Koehrsen M., Kodira C., Roberts A.D., Lauer G.M., Rosen H.R., Bihl F., Cerny A., Spengler U., Liu Z., Kim A.Y., Xing Y., Schneidewind A., Madey M.A., Fleckenstein J.F., Park V.M., Galagan J.E., Nusbaum C., Walker B.D., Lake-Bakaar G.V., Daar E.S., Jacobson I.M., Gomperts E.D., Edlin B.R., Donfield S.M., Chung R.T., Talal A.H., Marion T., Birren B.W., Henn M.R., Allen T.M. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
22. Lopez-Labrador F.X., Moya A., Gonzalez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral Ther. 2008, 13:481-494.
23. Matser A., Vanhommerig J., Schim van der Loeff M.F., Geskus R.B., de Vries H.J., Prins J.M., Prins M., Bruisten S.M. HIV-infected men who have sex with men who identify themselves as belonging to subcultures are at increased risk for hepatitis C infection. PLoS ONE 2013, 8:e57740.
24. Matthews G.V., Pham S.T., Hellard M., Grebely J., Zhang L., Oon A., Marks P., van I.W., Kaldor J.M., Lloyd A., Dore G.J., White P.A. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin. Infect. Dis. 2011, 52:803-811.
25. Morano J.P., Gibson B.A., Altice F.L. The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS ONE 2013, 8:e64321.
26. Nishijima T., Shimbo T., Komatsu H., Hamada Y., Gatanaga H., Oka S. Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo. J. Acquir. Immune Defic. Syndr. 2014, 65:213-217.
27. Orsetti E., Staffolani S., Gesuita R., De I.G., Marchionni E., Brescini L., Castelli P., Barchiesi F. Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals. Infection 2013, 41:987-990.
28. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
29. Ruf M., Cohuet S., Maguire H., Brant L.J., Ramsay M., Lattimore S., Delpech V. Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England. Euro Surveill. 2008, 13:19042.
30. Schmidt A.J., Falcato L., Zahno B., Burri A., Regenass S., Mullhaupt B., Bruggmann P. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?. BMC Public Health 2014, 14:3.
31. Sun H.Y., Chang S.Y., Yang Z.Y., Lu C.L., Wu H., Yeh C.C., Liu W.C., Hsieh C.Y., Hung C.C., Chang S.C. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J. Clin. Microbiol. 2012, 50:781-787.
32. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4. 0. Mol. Biol. Evol. 2007, 24:1596-1599.
33. Tseng Y.T., Sun H.Y., Chang S.Y., Wu C.H., Liu W.C., Wu P.Y., Lu C.L., Hsieh C.Y., Hung C.C. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. J. Formos. Med. Assoc. 2012, 111:431-438.
34. van der Helm J.J., Prins M., del A.J., Bucher H.C., Chene G., Dorrucci M., Gill J., Hamouda O., Sannes M., Porter K., Geskus R.B. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011, 25:1083-1091.
35. Wandeler G., Gsponer T., Bregenzer A., Gunthard H.F., Clerc O., Calmy A., Stockle M., Bernasconi E., Furrer H., Rauch A. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin. Infect. Dis. 2012, 55:1408-1416.
36. Witt M.D., Seaberg E.C., Darilay A., Young S., Badri S., Rinaldo C.R., Jacobson L.P., Detels R., Thio C.L. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin. Infect. Dis. 2013, 57:77-84.